{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T04:31:16Z","timestamp":1770438676803,"version":"3.49.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T00:00:00Z","timestamp":1768262400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T00:00:00Z","timestamp":1768262400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"DOI":"10.1007\/s12032-025-03213-2","type":"journal-article","created":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T06:22:03Z","timestamp":1768285323000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Synergistic inhibition of metastatic melanoma by carvacrol and chloroquine: an in vitro and in silico investigation of apoptosis and molecular targets"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0686-3953","authenticated-orcid":false,"given":"Patrycja","family":"K\u0142os","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siarhei","family":"Dabravolski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3193-4338","authenticated-orcid":false,"given":"Magdalena","family":"Peru\u017cy\u0144ska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alicja","family":"Przekop","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pawe\u0142","family":"Kostka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4809-415X","authenticated-orcid":false,"given":"Violetta","family":"Dziedziejko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6191-7168","authenticated-orcid":false,"given":"Marek","family":"Dro\u017adzik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4497-4395","authenticated-orcid":false,"given":"Dariusz","family":"Chlubek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9415-2758","authenticated-orcid":false,"given":"Krzysztof","family":"Safranow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,13]]},"reference":[{"key":"3213_CR1","doi-asserted-by":"publisher","first-page":"258","DOI":"10.3390\/plants12020258","volume":"12","author":"I Dincheva","year":"2023","unstructured":"Dincheva I, Badjakov I, Galunska B. New insights into the research of bioactive compounds from plant origins with nutraceutical and pharmaceutical potential. Plants. 2023;12:258. https:\/\/doi.org\/10.3390\/plants12020258.","journal-title":"Plants"},{"key":"3213_CR2","doi-asserted-by":"publisher","unstructured":"Goyal SN, Prajapati CP, Gore PR, Patil CR, Mahajan UB, Sharma C, Talla SP, Ojha SK. Therapeutic potential and pharmaceutical development of thymoquinone: A multitargeted molecule of natural origin. Front Pharmacol. 2017;8. https:\/\/doi.org\/10.3389\/fphar.2017.00656.","DOI":"10.3389\/fphar.2017.00656"},{"key":"3213_CR3","doi-asserted-by":"publisher","first-page":"3544","DOI":"10.1002\/fsn3.2994","volume":"10","author":"M Imran","year":"2022","unstructured":"Imran M, Aslam M, Alsagaby SA, Saeed F, Ahmad I, Afzaal M, Arshad MU, Abdelgawad MA, El-Ghorab AH, Khames A, et al. Therapeutic application of carvacrol: A comprehensive review. Food Sci Nutr. 2022;10:3544\u201361. https:\/\/doi.org\/10.1002\/fsn3.2994.","journal-title":"Food Sci Nutr"},{"key":"3213_CR4","doi-asserted-by":"publisher","unstructured":"Fatima K, Luqman S, Meena A. Carvacrol arrests the proliferation of hypopharyngeal carcinoma cells by suppressing ornithine decarboxylase and hyaluronidase activities. Front Nutr. 2022;9. https:\/\/doi.org\/10.3389\/fnut.2022.857256.","DOI":"10.3389\/fnut.2022.857256"},{"key":"3213_CR5","doi-asserted-by":"publisher","unstructured":"Sampaio LA, Pina LTS, Serafini MR, Tavares DDS, Guimar\u00e3es AG. Antitumor effects of carvacrol and thymol: A systematic review. Front Pharmacol. 2021;12. https:\/\/doi.org\/10.3389\/fphar.2021.702487.","DOI":"10.3389\/fphar.2021.702487"},{"key":"3213_CR6","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1080\/01635581.2017.1359321","volume":"69","author":"F Khan","year":"2017","unstructured":"Khan F, Khan I, Farooqui A, Ansari IA. Carvacrol induces reactive oxygen species (ROS)-Mediated apoptosis along with cell cycle arrest at G0\/G1in human prostate cancer cells. Nutr Cancer. 2017;69:1075\u201387. https:\/\/doi.org\/10.1080\/01635581.2017.1359321.","journal-title":"Nutr Cancer"},{"key":"3213_CR7","doi-asserted-by":"publisher","unstructured":"Wr\u00f3blewska-\u0141uczka P, Kulenty L, Za\u0142uska-Ogryzek K, G\u00f3ralczyk A, \u0141uszczki JJ. Screening of the Antimelanoma Activity of Monoterpenes\u2014In Vitro Experiments on Four Human Melanoma Lines. CIMB. 2025;47:97. https:\/\/doi.org\/10.3390\/cimb47020097","DOI":"10.3390\/cimb47020097"},{"key":"3213_CR8","unstructured":"American Cancer Society. Risk Factors for Melanoma Skin Cancer. https:\/\/www.cancer.org\/cancer\/types\/melanoma-skin-cancer\/causes-risks-prevention\/risk-factors.html"},{"key":"3213_CR9","doi-asserted-by":"crossref","unstructured":"Surgical Management of Melanoma. In Cutaneous Melanoma: Etiology and Therapy; Codon Publications. 2017. p. 91\u2013100. ISBN 978-0-9944381-4-0.","DOI":"10.15586\/codon.cutaneousmelanoma.2017.ch7"},{"key":"3213_CR10","doi-asserted-by":"publisher","first-page":"3535","DOI":"10.3390\/ijms21103535","volume":"21","author":"K Yang","year":"2020","unstructured":"Yang K, Oak ASW, Slominski RM, Bro\u017cyna AA, Slominski AT. Current molecular markers of melanoma and treatment targets. IJMS. 2020;21:3535. https:\/\/doi.org\/10.3390\/ijms21103535.","journal-title":"IJMS"},{"key":"3213_CR11","doi-asserted-by":"publisher","first-page":"221","DOI":"10.3390\/cancers13020221","volume":"13","author":"A Moreira","year":"2021","unstructured":"Moreira A, Heinzerling L, Bhardwaj N, Friedlander P. Curr Melanoma Treatments: where Do We Stand? Cancers. 2021;13:221. https:\/\/doi.org\/10.3390\/cancers13020221.","journal-title":"Curr Melanoma Treatments: where Do We Stand? Cancers"},{"key":"3213_CR12","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1056\/nejmoa2005493","volume":"383","author":"R Dummer","year":"2020","unstructured":"Dummer R, Hauschild A, Santinami M, Atkinson V, Mandal\u00e0 M, Kirkwood JM, Chiarion Sileni V, Larkin J, Nyakas M, Dutriaux C, et al. Five-Year analysis of adjuvant Dabrafenib plus Trametinib in stage III melanoma. N Engl J Med. 2020;383:1139\u201348. https:\/\/doi.org\/10.1056\/nejmoa2005493.","journal-title":"N Engl J Med"},{"key":"3213_CR13","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1056\/nejmoa1408868","volume":"371","author":"J Larkin","year":"2014","unstructured":"Larkin J, Ascierto PA, Dr\u00e9no B, Atkinson V, Liszkay G, Maio M, Mandal\u00e0 M, Demidov L, Stroyakovskiy D, Thomas L, et al. Combined Vemurafenib and Cobimetinib in BRAF-Mutated melanoma. N Engl J Med. 2014;371:1867\u201376. https:\/\/doi.org\/10.1056\/nejmoa1408868.","journal-title":"N Engl J Med"},{"key":"3213_CR14","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s41669-020-00206-x","volume":"5","author":"R Houten","year":"2021","unstructured":"Houten R, Greenhalgh J, Mahon J, Nevitt S, Beale S, Boland A, Lambe T, Dundar Y, Kotas E, McEntee J. Encorafenib with binimetinib for the treatment of patients with BRAF V600 Mutation-Positive unresectable or metastatic melanoma: an evidence review group perspective of a NICE single technology appraisal. PharmacoEconomics Open. 2021;5:13\u201322. https:\/\/doi.org\/10.1007\/s41669-020-00206-x.","journal-title":"PharmacoEconomics Open"},{"key":"3213_CR15","doi-asserted-by":"publisher","first-page":"2801","DOI":"10.3390\/cancers12102801","volume":"12","author":"I Proietti","year":"2020","unstructured":"Proietti I, Skroza N, Bernardini N, Tolino E, Balduzzi V, Marchesiello A, Michelini S, Volpe S, Mambrin A, Mangino G, et al. Mechanisms of acquired BRAF inhibitor resistance in melanoma: A systematic review. Cancers. 2020;12:2801. https:\/\/doi.org\/10.3390\/cancers12102801.","journal-title":"Cancers"},{"key":"3213_CR16","doi-asserted-by":"publisher","unstructured":"Adhikari S, Bhattacharya A, Adhikary S, Singh V, Gadad SS, Roy S, Das C. The paradigm of drug resistance in cancer: an epigenetic perspective. Biosci Rep. 2022;42. https:\/\/doi.org\/10.1042\/bsr20211812.","DOI":"10.1042\/bsr20211812"},{"key":"3213_CR17","doi-asserted-by":"publisher","unstructured":"Chang H, Zou Z. Targeting autophagy to overcome drug resistance: further developments. J Hematol Oncol. 2020;13. https:\/\/doi.org\/10.1186\/s13045-020-01000-2.","DOI":"10.1186\/s13045-020-01000-2"},{"key":"3213_CR18","doi-asserted-by":"publisher","unstructured":"Khan SU, Fatima K, Aisha S, Malik F. Unveiling the mechanisms and challenges of cancer drug resistance. Cell Commun Signal. 2024;22. https:\/\/doi.org\/10.1186\/s12964-023-01302-1.","DOI":"10.1186\/s12964-023-01302-1"},{"key":"3213_CR19","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.1016\/j.drudis.2020.09.010","volume":"25","author":"W Zhou","year":"2020","unstructured":"Zhou W, Wang H, Yang Y, Chen Z-S, Zou C, Zhang J. Chloroquine against Malaria, cancers and viral diseases. Drug Discovery Today. 2020;25:2012\u201322. https:\/\/doi.org\/10.1016\/j.drudis.2020.09.010.","journal-title":"Drug Discovery Today"},{"key":"3213_CR20","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1080\/15548627.2018.1474314","volume":"14","author":"M Mauthe","year":"2018","unstructured":"Mauthe M, Orhon I, Rocchi C, Zhou X, Luhr M, Hijlkema K-J, Coppes RP, Engedal N, Mari M, Reggiori F. Chloroquine inhibits autophagic flux by decreasing Autophagosome-Lysosome fusion. Autophagy. 2018;14:1435\u201355. https:\/\/doi.org\/10.1080\/15548627.2018.1474314.","journal-title":"Autophagy"},{"key":"3213_CR21","doi-asserted-by":"publisher","unstructured":"Verma AK, Bharti PS, Rafat S, Bhatt D, Goyal Y, Pandey KK, Ranjan S, Almatroodi SA, Alsahli MA, Rahmani AH, et al. Autophagy paradox of cancer: Role, Regulation, and duality. Oxidative Med Cell Longev. 2021;2021. https:\/\/doi.org\/10.1155\/2021\/8832541.","DOI":"10.1155\/2021\/8832541"},{"key":"3213_CR22","doi-asserted-by":"publisher","unstructured":"Xie X, Koh JY, Price S, White E, Mehnert JM. Atg7 Overcomes Senescence and Promotes Growth of BrafV600E-Driven Melanoma. Cancer Discovery. 2015;5:410\u2013423. https:\/\/doi.org\/10.1158\/2159-8290.cd-14-1473","DOI":"10.1158\/2159-8290.cd-14-1473"},{"key":"3213_CR23","doi-asserted-by":"publisher","first-page":"6374","DOI":"10.1158\/1078-0432.ccr-20-1675","volume":"26","author":"A Truong","year":"2020","unstructured":"Truong A, Yoo JH, Scherzer MT, Sanchez JMS, Dale KJ, Kinsey CG, Richards JR, Shin D, Ghazi PC, Onken MD, et al. Chloroquine SensitizesGNAQ\/11-Mutated melanoma to MEK1\/2 Inhibition. Clin Cancer Res. 2020;26:6374\u201386. https:\/\/doi.org\/10.1158\/1078-0432.ccr-20-1675.","journal-title":"Clin Cancer Res"},{"key":"3213_CR24","doi-asserted-by":"publisher","first-page":"6777","DOI":"10.2147\/ijn.s458910","volume":"19","author":"Y Liu","year":"2024","unstructured":"Liu Y, Meng Y, Zhang J, Gu L, Shen S, Zhu Y, Wang J. Pharmacology progresses and applications of chloroquine in cancer therapy. IJN. 2024;19:6777\u2013809. https:\/\/doi.org\/10.2147\/ijn.s458910.","journal-title":"IJN"},{"key":"3213_CR25","doi-asserted-by":"publisher","unstructured":"Braga CBE, Martins AC, Cayotopa ADE, Klein WW, Schlosser AR, Silva AFD, Souza MND, Andrade BWB, Filgueira-J\u00fanior JA, Pinto WDJ et al. Side Effects of Chloroquine and Primaquine and Symptom Reduction in Malaria Endemic Area (M\u00e2ncio Lima, Acre, Brazil). Interdisciplinary Perspectives on Infectious Diseases. 2015;2015:1\u20137. https:\/\/doi.org\/10.1155\/2015\/346853","DOI":"10.1155\/2015\/346853"},{"key":"3213_CR26","doi-asserted-by":"publisher","first-page":"3126","DOI":"10.3390\/cancers15123126","volume":"15","author":"K-M Plachouri","year":"2023","unstructured":"Plachouri K-M, Florou V, Georgiou V, Georgiou S. Cutaneous side effects of modern targeted therapy and immunotherapy in patients with dermatological malignancies. Cancers. 2023;15:3126. https:\/\/doi.org\/10.3390\/cancers15123126.","journal-title":"Cancers"},{"key":"3213_CR27","doi-asserted-by":"publisher","unstructured":"Qian J, Wan J, Yao Q, Chen Y, Ling T, Zhang Y, Tang Z. Cutaneous adverse events associated with BRAF and MEK inhibitors: A systematic review and Meta-Analysis. Front Pharmacol. 2024;15. https:\/\/doi.org\/10.3389\/fphar.2024.1457226.","DOI":"10.3389\/fphar.2024.1457226"},{"key":"3213_CR28","doi-asserted-by":"publisher","unstructured":"Muto Y, Fujimura T, Kambayashi Y, Ohuchi K, Amagai R, Okuma T, Furudate S, Hashimoto A, Aiba S. Erythema nodosum developed in a patient with advanced cutaneous melanoma treated with Dabrafenib plus Trametinib combination therapy. Dermatol Ther. 2020;33. https:\/\/doi.org\/10.1111\/dth.14430.","DOI":"10.1111\/dth.14430"},{"key":"3213_CR29","doi-asserted-by":"publisher","first-page":"121","DOI":"10.3892\/ol.2013.1648","volume":"7","author":"R Yao","year":"2014","unstructured":"Yao R, Zheng J, Zheng W, Gong Y, Liu W, Xing R. VX680 suppresses the growth of HepG2 cells and enhances the chemosensitivity to cisplatin. Oncol Lett. 2014;7:121\u20134. https:\/\/doi.org\/10.3892\/ol.2013.1648.","journal-title":"Oncol Lett"},{"key":"3213_CR30","doi-asserted-by":"crossref","unstructured":"Zhang X, Huang J, Yu C, Xiang L, Li L, Shi D, Lin F. Quercetin Enhanced Paclitaxel Therapeutic Effects Towards PC-3 Prostate Cancer Through ER Stress Induction and ROS Production. Onco Targets Ther. 2020;13. https:\/\/www.dovepress.com\/quercetin-enhanced-paclitaxel-therapeutic-effects-towards-pc-3-prostat-peer-reviewed-fulltext-article-OTT","DOI":"10.2147\/OTT.S228453"},{"key":"3213_CR31","doi-asserted-by":"publisher","unstructured":"S\u00e1nchez BG, Bort A, Mateos-G\u00f3mez PA, Rodr\u00edguez-Henche N, D\u00edaz-Laviada I. Combination of the natural product capsaicin and docetaxel synergistically kills human prostate cancer cells through the metabolic regulator AMP-Activated kinase. Cancer Cell Int. 2019;19. https:\/\/doi.org\/10.1186\/s12935-019-0769-2.","DOI":"10.1186\/s12935-019-0769-2"},{"key":"3213_CR32","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2017.7664","author":"Y Liu","year":"2017","unstructured":"Liu Y, Yue C, Li J, Wu J, Wang S, Sun D, Guo Y, Lin Z, Zhang D, Wang R. Enhancement of cisplatin cytotoxicity by retigeric acid B involves blocking DNA repair and activating DR5 in prostate cancer cells. Oncol Lett. 2017. https:\/\/doi.org\/10.3892\/ol.2017.7664.","journal-title":"Oncol Lett"},{"key":"3213_CR33","doi-asserted-by":"publisher","first-page":"9703","DOI":"10.2147\/IJN.S274083","volume":"15","author":"Y Hu","year":"2020","unstructured":"Hu Y, Ran M, Wang B, Lin Y, Cheng Y, Zheng S. Co-Delivery of Docetaxel and Curcumin via Nanomicelles for Enhancing Anti-Ovarian Cancer Treatment. Int J Nanomedicine. 2020; 15:9703-9715. https:\/\/pubmed.ncbi.nlm.nih.gov\/33299312\/","journal-title":"Int J Nanomedicine"},{"key":"3213_CR34","doi-asserted-by":"publisher","unstructured":"Seca A, Pinto D. Plant secondary metabolites as anticancer agents: successes in clinical trials and therapeutic application. IJMS. 2018;19(263). https:\/\/doi.org\/10.3390\/ijms19010263.","DOI":"10.3390\/ijms19010263"},{"key":"3213_CR35","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.jss.2013.04.055","volume":"184","author":"ME Egger","year":"2013","unstructured":"Egger ME, Huang JS, Yin W, McMasters KM, McNally LR. Inhibition of autophagy with chloroquine is effective in melanoma. J Surg Res. 2013;184:274\u201381. https:\/\/doi.org\/10.1016\/j.jss.2013.04.055.","journal-title":"J Surg Res"},{"key":"3213_CR36","doi-asserted-by":"publisher","unstructured":"Ranjitkar S, Zhang D, Sun F, Salman S, He W, Venkitanarayanan K, Tulman ER, Tian X. Cytotoxic effects on cancerous and Non-Cancerous cells of Trans-Cinnamaldehyde, Carvacrol, and Eugenol. Sci Rep. 2021;11. https:\/\/doi.org\/10.1038\/s41598-021-95394-9.","DOI":"10.1038\/s41598-021-95394-9"},{"key":"3213_CR37","doi-asserted-by":"publisher","first-page":"118894","DOI":"10.1016\/j.lfs.2020.118894","volume":"266","author":"L Li","year":"2021","unstructured":"Li L, He L, Wu Y, Zhang Y. Carvacrol affects breast cancer cells through TRPM7 mediated cell cycle regulation. Life Sci. 2021;266:118894. https:\/\/doi.org\/10.1016\/j.lfs.2020.118894.","journal-title":"Life Sci"},{"key":"3213_CR38","doi-asserted-by":"publisher","unstructured":"Elahi MG, Hekmati M, Esmaeili D, Ziarati P, Yousefi M. Evaluation and efficacy modified carvacrol and Anti-Cancer peptide against cell line gastric AGS. Int J Pept Res Ther. 2022;28. https:\/\/doi.org\/10.1007\/s10989-022-10426-w.","DOI":"10.1007\/s10989-022-10426-w"},{"key":"3213_CR39","doi-asserted-by":"publisher","first-page":"2638","DOI":"10.3390\/pharmaceutics14122638","volume":"14","author":"MI Rodr\u00edguez-L\u00f3pez","year":"2022","unstructured":"Rodr\u00edguez-L\u00f3pez MI, Mercader-Ros MT, P\u00e9rez-Garrido A, P\u00e9rez-S\u00e1nchez H, Pellicer JA, Lucas-Abell\u00e1n C, Montoro-Garc\u00eda S, Y\u00e1\u00f1ez-Gasc\u00f3n MJ, Gil-Izquierdo \u00c1, N\u00fa\u00f1ez-Delicado E, et al. Carvacrol and HP-\u03b2-Cyclodextrin complexes: extensive characterization and potential cytotoxic effect in human colorectal carcinoma cells. Pharmaceutics. 2022;14:2638. https:\/\/doi.org\/10.3390\/pharmaceutics14122638.","journal-title":"Pharmaceutics"},{"key":"3213_CR40","doi-asserted-by":"publisher","unstructured":"Yin X, Chen H, Chen S, Zhang S. Screening and Validation of a Carvacrol-Targeting Viability-Regulating Protein, SLC6A3, in Liver Hepatocellular Carcinoma. Disease Markers.2022;2022:1\u201315. https:\/\/doi.org\/10.1155\/2022\/3736104.","DOI":"10.1155\/2022\/3736104"},{"key":"3213_CR41","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1111\/ejn.15647","volume":"55","author":"R Alanazi","year":"2022","unstructured":"Alanazi R, Nakatogawa H, Wang H, Ji D, Luo Z, Golbourn B, Feng Z, Rutka JT, Sun H. Inhibition of TRPM7 with carvacrol suppresses glioblastoma functions in vivo. Eur J Neurosci. 2022;55:1483\u201391. https:\/\/doi.org\/10.1111\/ejn.15647.","journal-title":"Eur J Neurosci"},{"key":"3213_CR42","doi-asserted-by":"publisher","unstructured":"Moradipour A, Dariushnejad H, Ahmadizadeh C, Lashgarian HE. Dietary flavonoid carvacrol triggers the apoptosis of human breast cancer MCF-7 cells via the P53\/Bax\/Bcl-2 axis. Med Oncol. 2022;40. https:\/\/doi.org\/10.1007\/s12032-022-01918-2.","DOI":"10.1007\/s12032-022-01918-2"},{"key":"3213_CR43","doi-asserted-by":"publisher","unstructured":"Yang J, Guo Z, Liu X, Liu Q, Wu M, Yao X, Liu Y, Cui C, Li H, Song C, et al. Cytotoxicity evaluation of chloroquine and hydroxychloroquine in multiple cell lines and tissues by dynamic imaging system and physiologically based Pharmacokinetic model. Front Pharmacol. 2020;11. https:\/\/doi.org\/10.3389\/fphar.2020.574720.","DOI":"10.3389\/fphar.2020.574720"},{"key":"3213_CR44","doi-asserted-by":"publisher","unstructured":"Azimi S, Esmaeil Lashgarian H, Ghorbanzadeh V, Moradipour A, Pirzeh L, Dariushnejad H. 5-FU and the dietary flavonoid carvacrol: A synergistic combination that induces apoptosis in MCF-7 breast cancer cells. Med Oncol. 2022;39. https:\/\/doi.org\/10.1007\/s12032-022-01863-0.","DOI":"10.1007\/s12032-022-01863-0"},{"key":"3213_CR45","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2019.10308","author":"J Wang","year":"2019","unstructured":"Wang J, Wang C, Hu X, Yu C, Zhou L, Ding Z, Zhou M. Gefitinib-mediated apoptosis is enhanced via Inhibition of autophagy by chloroquine diphosphate in cutaneous squamous cell carcinoma cells. Oncol Lett. 2019. https:\/\/doi.org\/10.3892\/ol.2019.10308.","journal-title":"Oncol Lett"},{"key":"3213_CR46","doi-asserted-by":"publisher","unstructured":"Eloranta K, Cairo S, Liljestr\u00f6m E, Soini T, Kyr\u00f6nlahti A, Judde J-G, Wilson DB, Heikinheimo M, Pihlajoki M. Chloroquine triggers cell death and inhibits PARPs in cell models of aggressive hepatoblastoma. Front Oncol. 2020;10. https:\/\/doi.org\/10.3389\/fonc.2020.01138.","DOI":"10.3389\/fonc.2020.01138"},{"key":"3213_CR47","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1007\/s11655-020-3193-5","volume":"27","author":"A Mari","year":"2021","unstructured":"Mari A, Mani G, Nagabhishek SN, Balaraman G, Subramanian N, Mirza FB, Sundaram J, Thiruvengadam D. Carvacrol promotes cell cycle arrest and apoptosis through PI3K\/AKT signaling pathway in MCF-7 breast cancer cells. Chin J Integr Med. 2021;27:680\u20137. https:\/\/doi.org\/10.1007\/s11655-020-3193-5.","journal-title":"Chin J Integr Med"},{"key":"3213_CR48","doi-asserted-by":"publisher","first-page":"2848","DOI":"10.3390\/nu14142848","volume":"14","author":"A Gunes-Bayir","year":"2022","unstructured":"Gunes-Bayir A, Guler EM, Bilgin MG, Ergun IS, Kocyigit A, Dadak A. Anti-Inflammatory and antioxidant effects of carvacrol on N-Methyl-N\u2032-Nitro-N-Nitrosoguanidine (MNNG) induced gastric carcinogenesis in Wistar rats. Nutrients. 2022;14:2848. https:\/\/doi.org\/10.3390\/nu14142848.","journal-title":"Nutrients"},{"key":"3213_CR49","doi-asserted-by":"publisher","unstructured":"Shen S, Shao Y, Li C. Different types of cell death and their shift in shaping disease. Cell Death Discov. 2023;9. https:\/\/doi.org\/10.1038\/s41420-023-01581-0.","DOI":"10.1038\/s41420-023-01581-0"},{"key":"3213_CR50","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1158\/1535-7163.mct-22-0147","volume":"22","author":"D Lapadula","year":"2023","unstructured":"Lapadula D, Lam B, Terai M, Sugase T, Tanaka R, Farias E, Kadamb R, Lopez-Anton M, Heine CC, Modasia B, et al. IGF1R Inhibition enhances the therapeutic effects of Gq\/11 Inhibition in metastatic uveal melanoma progression. Mol Cancer Ther. 2023;22:63\u201374. https:\/\/doi.org\/10.1158\/1535-7163.mct-22-0147.","journal-title":"Mol Cancer Ther"},{"key":"3213_CR51","doi-asserted-by":"publisher","first-page":"82511","DOI":"10.18632\/oncotarget.12733","volume":"7","author":"V Le Coz","year":"2016","unstructured":"Le Coz V, Zhu C, Devocelle A, Vazquez A, Boucheix C, Azzi S, Gallerne C, Eid P, Lecourt S, Giron-Michel J. IGF-1 contributes to the expansion of Melanoma-Initiating cells through an Epithelial-Mesenchymal transition process. Oncotarget. 2016;7:82511\u201327. https:\/\/doi.org\/10.18632\/oncotarget.12733.","journal-title":"Oncotarget"},{"key":"3213_CR52","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1021\/acs.jmedchem.6b01690","volume":"60","author":"S Sundriyal","year":"2017","unstructured":"Sundriyal S, Moniot S, Mahmud Z, Yao S, Di Fruscia P, Reynolds CR, Dexter DT, Sternberg MJE, Lam EW-F, Steegborn C, et al. Thienopyrimidinone based Sirtuin-2 (SIRT2)-Selective inhibitors bind in the ligand induced selectivity pocket. J Med Chem. 2017;60:1928\u201345. https:\/\/doi.org\/10.1021\/acs.jmedchem.6b01690.","journal-title":"J Med Chem"},{"key":"3213_CR53","doi-asserted-by":"publisher","first-page":"673","DOI":"10.3390\/cancers11050673","volume":"11","author":"I Karwaciak","year":"2019","unstructured":"Karwaciak I, Sa\u0142kowska A, Kara\u015b K, Sobalska-Kwapis M, Walczak-Drzewiecka A, Pu\u0142aski \u0141, Strapagiel D, Dastych J, Ratajewski M. SIRT2 contributes to the resistance of melanoma cells to the multikinase inhibitor dasatinib. Cancers. 2019;11:673. https:\/\/doi.org\/10.3390\/cancers11050673.","journal-title":"Cancers"},{"key":"3213_CR54","first-page":"5334","volume":"56","author":"J Portela Passos","year":"2015","unstructured":"Portela Passos J, Dias ABT, Zoroquiain P, Mastromonaco C, Alghamdi S. Sirtuin 2 expression in uveal melanoma correlates with metastasis in an animal model. Investig Ophthalmol Vis Sci. 2015;56:5334\u20135334.","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"3213_CR55","doi-asserted-by":"publisher","unstructured":"Li Z-N, Luo Y. HSP90 inhibitors and cancer: prospects for use in targeted therapies (Review). Oncol Rep. 2022;49. https:\/\/doi.org\/10.3892\/or.2022.8443.","DOI":"10.3892\/or.2022.8443"},{"key":"3213_CR56","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.1016\/j.bmcl.2011.02.101","volume":"21","author":"CW Zapf","year":"2011","unstructured":"Zapf CW, Bloom JD, McBean JL, Dushin RG, Nittoli T, Ingalls C, Sutherland AG, Sonye JP, Eid CN, Golas J, et al. Design and SAR of macrocyclic Hsp90 inhibitors with increased metabolic stability and potent Cell-Proliferation activity. Bioorg Med Chem Lett. 2011;21:2278\u201382. https:\/\/doi.org\/10.1016\/j.bmcl.2011.02.101.","journal-title":"Bioorg Med Chem Lett"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-025-03213-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-025-03213-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-025-03213-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T14:46:25Z","timestamp":1770389185000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12032-025-03213-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,13]]},"references-count":56,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["3213"],"URL":"https:\/\/doi.org\/10.1007\/s12032-025-03213-2","relation":{},"ISSN":["1559-131X"],"issn-type":[{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,13]]},"assertion":[{"value":"31 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"113"}}